Every year, **Clostridioides difficile** — C. diff — kills hundreds of thousands of people worldwide. It's one of the most feared hospital-acquired infections in medicine: a gut bacterium that takes hold when antibiotics wipe out normal protective gut flora, causing explosive diarrhoea, inflammation of the colon, and in severe cases, death.
The cruel irony is that the antibiotics used to *treat* C. diff — primarily vancomycin and fidaxomicin — also damage the very gut microbiome that protects against reinfection. So patients clear the infection, then relapse. And relapse again. Recurrence rates are notoriously high — up to 35% after a first episode, rising with each subsequent infection.
Now, scientists at **Leiden University** have developed something that may break this cycle entirely: a next-generation antibiotic called **EVG7**.
**What Is EVG7?**
EVG7 is a **glycopeptide antibiotic** — the same broad class as vancomycin, but engineered to be dramatically more potent and far more selective. Named after PhD candidate **Emma van Groesen** and its position as the seventh most active compound in the research series, it was developed in the lab of **Professor Nathaniel Martin** at Leiden University's Institute of Biology, in collaboration with **NC State University's Casey Theriot**.
The findings, published in *Nature Communications*, reveal its advantages:
- **16× more potent** against clinical C. difficile isolates than vancomycin — at a tiny fraction of the dose - Effective even at very low concentrations, reducing systemic exposure - **Spares the Lachnospiraceae** — a family of beneficial gut bacteria that are natural defenders against C. diff colonisation - In mouse models, **prevents recurrence** — the most persistent and dangerous feature of C. diff infection - Potentially less toxic to kidneys than existing glycopeptides
**Why Sparing the Microbiome Changes Everything**
This is the critical innovation. Current treatments clear C. diff — but they also obliterate the protective bacterial ecosystem that keeps C. diff from coming back. It's like dousing a grass fire with a flood that kills all the grass, leaving bare soil for the fire to return to.
EVG7's selectivity changes that equation. It targets *C. difficile* with extreme precision while leaving protective Lachnospiraceae populations largely intact. Patients could clear the infection *and* maintain the biological defences that prevent it returning.
"EVG7 is up to 16 times more active against C. difficile clinical isolates than vancomycin," the researchers wrote — a striking result for a field that has seen very limited innovation in C. diff treatment options.
**The Timeline**
EVG7 is currently at the **preclinical stage** — tested successfully in mouse models, not yet in humans. The team anticipates approximately **two to three years** of further development before human trials could begin. Regulatory pathways for novel antibiotics, particularly for serious hospital-acquired infections, are well-established, and interest from pharmaceutical partners is expected to be strong.
**The Antibiotic Resistance Context**
The WHO lists C. difficile as one of the highest-priority pathogens requiring new treatments. Globally, the pipeline for new antibiotics has been thin for decades — few pharmaceutical companies invest in them because the economics are challenging. EVG7 represents exactly the kind of targeted, high-potency, microbiome-aware antibiotic the field urgently needs.
A more powerful weapon. A kinder one. One that helps the body rebuild what it needs to stay healthy long-term. 💊🦠✅
*Sources: Nature Communications · Leiden University Institute of Biology · NC State University · ScienceDaily · Technology Networks · Published October 2025, widely reported March 2026*
